BRCA1 and neoplasm: Interestingly, there is a clinical trial recruiting patients with advanced BC with BRCA1/2 promoter hypermethylation to analyze the response to olaparib monotherapy, which includes tumor sample collection for biomarker analysis (NCT03205761).